Buflomedil hydrochloride (Fonzylane), a vasodilator, is used in therapy of claudication or the symptoms of the peripheral arterial disease.

Buflomedil enhances intracellular cAMP levels in human keratinocytes, either secondary to adenyl-cyclase stimulation (BC) or phosphodiesterase inhibition (PTX). Buflomedil diminishes release of TPA-induced TNF-alpha and IL-8 in keratinocytes; in the case of IL-8, this inhibition may occur to transcriptional level. At the micromolar level, Buflomedil notably inhibits epinephrine-induced aggregation. Buflomedil leads to a weak inhibition of collagen- and ADP-induced aggregation. Buflomedil inhibits grainy secretion and the interaction of fibrinogen with its receptor on platelet. the capillary perfusion is improved by Buflomedil hypochloride in such related situations, evoking a possible effect upon neutrophils. Buflomedil Completely inhibits adhesion of histamine related neutrophil (flow system) and partially inhibits adhesion after IL-1-4 hours (flow and stable systems). Buflomedil lowers the hypoxia-induced neutrophil adhesion and expression of P-selectin at the surface of endothelial cells.